Media Contacts USMedia@galderma.com Zach Randles-Friedman, Head of U.S. Communications: +1 305 299 5700 Filter news by date News Tags - Any -CampaignPress Releases Month MonthJanuaryFebruaryMarchAprilMayJuneJulyAugustSeptemberOctoberNovemberDecember Year Year20242023202220212020201920182017201620152014201320122011 Apply 8 . 1 . 2014 Press Releases The Cetaphil® Brand Unveils New Limited Edition Packaging for Camp Wonder 7 . 10 . 2014 Press Releases Galderma Finalizes Major Expansion in Aesthetic and Corrective Dermatology in the U.S. and Canada 5 . 28 . 2014 Press Releases Galderma to gain rights to Restylane®, Perlane®, Sculptra® and Dysport® in the United States and Canada 4 . 22 . 2014 Press Releases Cetaphil Brand Unveils First Fully Integrated Campaign: “Gentle Power” 3 . 22 . 2014 Press Releases Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosacea 2 . 11 . 2014 Press Releases Nestlé Skin Health Is Created Targeting Global Skin Health Needs 1 . 29 . 2014 Press Releases Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso® Gel for Treatment of Persistent Erythema of Rosacea 1 . 8 . 2014 Press Releases Galderma Announces CEO for North American Operations 10 . 17 . 2013 Press Releases Galderma Serves as Premier Sponsor for 2013 Commit to Cure Gala Benefiting National Psoriasis Foundation 10 . 2 . 2013 Press Releases The Cetaphil® Brand Unveils New Limited‐Edition Packaging for Camp Wonder 9 . 11 . 2013 Press Releases Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship 8 . 26 . 2013 Press Releases Galderma Receives FDA Approval of Mirvaso®: the First and Only FDA Approved Topical Treatment Specifically Developed and Indicated for the Facial Erythema of Rosacea Pagination Previous page Previous Page Next page Next Page
